J.P. Morgan downgrades Bruker to Neutral and maintains a $70 price target
J.P. Morgan lowered its rating on Bruker Corporation from Overweight to Neutral on October 14, 2026. Analyst Casey Woodring kept a $70 price target but warned that the company's exposure to the Academia & Government segment creates revenue uncertainty. The same coverage review also moved Sotera Health to Underweight with a reduced target of $17. The downgrade reflects limited visibility for the next 12 months.
Why it matters
The downgrade signals reduced confidence in Bruker's near‑term growth, which could weigh on the stock price (the analyst notes the shares trade at a discount until visibility improves). Sotera's lower rating and target may also pressure its share price.
Key facts
- 1J.P. Morgan downgraded Bruker from Overweight to Neutral. marketscreener.com
- 2Analyst Casey Woodring maintained a $70 price target for Bruker. tradingview.com
- 3J.P. Morgan set a $70 price target for Bruker. gurufocus.com
- 4J.P. Morgan set a $60 price target for Bruker. marketscreener.com
- 5J.P. Morgan downgraded Sotera Health to Underweight. tradingview.com
- 6The Sotera price target was lowered to $17 from $18. tradingview.com
Open questions
- Conflicting price targets for Bruker: $60 versus $70.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.